vs
Side-by-side financial comparison of ARDELYX, INC. (ARDX) and SONIDA SENIOR LIVING, INC. (SNDA). Click either name above to swap in a different company.
SONIDA SENIOR LIVING, INC. is the larger business by last-quarter revenue ($97.7M vs $94.5M, roughly 1.0× ARDELYX, INC.). SONIDA SENIOR LIVING, INC. runs the higher net margin — -30.5% vs -39.8%, a 9.3% gap on every dollar of revenue. On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs 6.2%). Over the past eight quarters, SONIDA SENIOR LIVING, INC.'s revenue compounded faster (20.3% CAGR vs 13.6%).
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
Sonida Senior Living, Inc. is a leading owner, operator and investor in senior housing communities in the United States in terms of resident capacity. The company and its predecessors have provided senior housing since 1990. As of June 1, 2025, the company operated 96 senior housing communities in 20 states with an aggregate capacity of approximately 10,000+ residents, including 83 senior housing communities that the company owns and 13 communities that the company manages on behalf of third ...
ARDX vs SNDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.5M | $97.7M |
| Net Profit | $-37.6M | $-29.8M |
| Gross Margin | — | — |
| Operating Margin | — | -30.8% |
| Net Margin | -39.8% | -30.5% |
| Revenue YoY | 27.5% | 6.2% |
| Net Profit YoY | — | -441.0% |
| EPS (diluted) | $-0.15 | $-1.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $94.5M | — | ||
| Q4 25 | $125.2M | $97.7M | ||
| Q3 25 | $110.3M | $98.0M | ||
| Q2 25 | $97.7M | $93.5M | ||
| Q1 25 | $74.1M | $91.9M | ||
| Q4 24 | $116.1M | $91.9M | ||
| Q3 24 | $98.2M | $74.8M | ||
| Q2 24 | $73.2M | $70.2M |
| Q1 26 | $-37.6M | — | ||
| Q4 25 | $-407.0K | $-29.8M | ||
| Q3 25 | $-969.0K | $-26.9M | ||
| Q2 25 | $-19.1M | $-1.6M | ||
| Q1 25 | $-41.1M | $-12.5M | ||
| Q4 24 | $4.6M | $-5.5M | ||
| Q3 24 | $-809.0K | $-13.8M | ||
| Q2 24 | $-16.5M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | — | ||
| Q3 24 | 84.0% | — | ||
| Q2 24 | 87.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | -30.8% | ||
| Q3 25 | 4.2% | -27.8% | ||
| Q2 25 | -14.7% | -2.0% | ||
| Q1 25 | -49.0% | 21.9% | ||
| Q4 24 | 7.0% | -6.7% | ||
| Q3 24 | 2.3% | -19.0% | ||
| Q2 24 | -18.6% | -13.9% |
| Q1 26 | -39.8% | — | ||
| Q4 25 | -0.3% | -30.5% | ||
| Q3 25 | -0.9% | -27.4% | ||
| Q2 25 | -19.5% | -1.7% | ||
| Q1 25 | -55.5% | -13.6% | ||
| Q4 24 | 4.0% | -6.0% | ||
| Q3 24 | -0.8% | -18.4% | ||
| Q2 24 | -22.5% | -14.0% |
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.01 | $-1.73 | ||
| Q3 25 | $0.00 | $-1.56 | ||
| Q2 25 | $-0.08 | $-0.16 | ||
| Q1 25 | $-0.17 | $-0.77 | ||
| Q4 24 | $0.01 | $-0.86 | ||
| Q3 24 | $0.00 | $-0.98 | ||
| Q2 24 | $-0.07 | $-0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.1M | $11.0M |
| Total DebtLower is stronger | $203.5M | $689.7M |
| Stockholders' EquityBook value | $148.6M | $-11.0K |
| Total Assets | $504.5M | $844.8M |
| Debt / EquityLower = less leverage | 1.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $238.1M | — | ||
| Q4 25 | $68.0M | $11.0M | ||
| Q3 25 | $42.7M | $17.0M | ||
| Q2 25 | $90.0M | $14.1M | ||
| Q1 25 | $30.8M | $14.0M | ||
| Q4 24 | $64.9M | $17.0M | ||
| Q3 24 | $47.4M | $24.9M | ||
| Q2 24 | $41.9M | $9.5M |
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | $689.7M | ||
| Q3 25 | $202.1M | $684.4M | ||
| Q2 25 | $201.4M | $677.9M | ||
| Q1 25 | $151.3M | $650.9M | ||
| Q4 24 | $150.9M | $651.4M | ||
| Q3 24 | $100.7M | $604.1M | ||
| Q2 24 | $100.2M | $583.8M |
| Q1 26 | $148.6M | — | ||
| Q4 25 | $166.9M | $-11.0K | ||
| Q3 25 | $154.3M | $29.8M | ||
| Q2 25 | $139.5M | $56.7M | ||
| Q1 25 | $145.7M | $58.8M | ||
| Q4 24 | $173.3M | $71.8M | ||
| Q3 24 | $158.3M | $77.5M | ||
| Q2 24 | $147.0M | $-34.1M |
| Q1 26 | $504.5M | — | ||
| Q4 25 | $501.6M | $844.8M | ||
| Q3 25 | $486.2M | $854.8M | ||
| Q2 25 | $466.8M | $849.8M | ||
| Q1 25 | $410.2M | $824.5M | ||
| Q4 24 | $435.8M | $841.9M | ||
| Q3 24 | $367.9M | $796.2M | ||
| Q2 24 | $343.5M | $652.2M |
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | 22.99× | ||
| Q2 25 | 1.44× | 11.96× | ||
| Q1 25 | 1.04× | 11.08× | ||
| Q4 24 | 0.87× | 9.07× | ||
| Q3 24 | 0.64× | 7.79× | ||
| Q2 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-400.0K |
| Free Cash FlowOCF − Capex | — | $-9.3M |
| FCF MarginFCF / Revenue | — | -9.5% |
| Capex IntensityCapex / Revenue | — | 9.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-8.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $21.0M | $-400.0K | ||
| Q3 25 | $365.0K | $12.0M | ||
| Q2 25 | $-25.3M | $8.9M | ||
| Q1 25 | $-38.5M | $3.8M | ||
| Q4 24 | $9.8M | $-3.1M | ||
| Q3 24 | $501.0K | $3.0M | ||
| Q2 24 | $-19.4M | $2.5M |
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $-9.3M | ||
| Q3 25 | $209.0K | $3.0M | ||
| Q2 25 | $-26.0M | $1.9M | ||
| Q1 25 | $-38.8M | $-4.5M | ||
| Q4 24 | $9.2M | $-10.4M | ||
| Q3 24 | $364.0K | $-5.1M | ||
| Q2 24 | $-19.5M | $-1.7M |
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | -9.5% | ||
| Q3 25 | 0.2% | 3.0% | ||
| Q2 25 | -26.6% | 2.1% | ||
| Q1 25 | -52.3% | -4.9% | ||
| Q4 24 | 7.9% | -11.3% | ||
| Q3 24 | 0.4% | -6.8% | ||
| Q2 24 | -26.7% | -2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 9.1% | ||
| Q3 25 | 0.1% | 9.2% | ||
| Q2 25 | 0.7% | 7.5% | ||
| Q1 25 | 0.4% | 9.1% | ||
| Q4 24 | 0.5% | 7.9% | ||
| Q3 24 | 0.1% | 10.8% | ||
| Q2 24 | 0.2% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
SNDA
| Health Care Resident Service | $86.3M | 88% |
| Community Reimbursement Revenue | $10.3M | 11% |
| Management Service | $1.1M | 1% |
